Gupta S, Afaq F, Mukhtar H. Selective growth-inhibitory, cell-cycle deregulatory and apoptotic response of apigenin in normal versus human prostate carcinoma cells. Biochem and Biophys Res Commun 2001; 287: 914-20.
Silvan S, Manoharan S, Baskaran N, Karthikeyan S, Prabhakar MM. Protective effect of apigenin on 7, 12-Dimethybenz(A) anthracene induced glycoconjugates in the plasma and buccal mucosa of golden Syrian hamsters. Int J Pharm Sci Res 2011; 1753-8.
Masuelli L, Benvenuto M, Mattera R, Di Stefano E, Zago E, Taffera G, et al. In vitro and in vivo anti-tumoral effects of the flavonoid apigenin in malignant mesothelioma. Front Pharmacol 2017; 8: 373.
Yang J, Pi C, Wang G. Inhibition of PI3K/Akt/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells. Biomed Pharmacother 2018; 103: 699-707.
Gutierrez-Uribe JA, Serna-Saldivar SRO, Moreno-Cuevas JE, Hernandez-Brenes C, Guajardo-Touche EM. Cancer cell
growth inhibition by black bean (Phaseolus vulgaris L) extracts US7763292. (2010).
Uckun FM. EGF-Genistein conjugates for the treatment of cancer US5911995. (1999).
Wen-zhe MA. Use of nobiletin in cancer treatment US9808477. (2017).
Young C. Methods and compositions for inhibiting the proliferation
of prostate cancer cells US6680342. (2004).
Walle T. A method of treating colon cancer by administering apigenin,
luteolin, diosmetin and chrysin WO2001058410. (2001).
Liu Y. A kind of chrysin phenylalanine derivative with anti-lung
cancer activity CN109824642. (2019).
Mukhtar H, Khan N, Mohammad A, Afaq F. Methods of treating
androgen dependent prostate cancer by administering an active
pharmaceutical ingredient being fisetin, 3,3',4',7-tetrahydroxyflavone
or a derivative thereof, in an oral, transdermal or topical
dosage form US20100010078. (2010).
Young SS. Use in anti-cancer agent of 4'-o-glucose-luteolin KR20100134966. (2010).
Nakajima N, Kawashima N. Cancer proliferation inhibitor JP2012025724. (2012).
Vorsa N, Vvedenskaya IO, Huang M-T, Rosen LRSL. Antiinflammatory
cranberry flavonol extract preparations US7270837. (2007).
Yuen K. Baicalin and its derivatives as a treatment for SARS
corona virus infection or other related infections WO2005044291. (2005).
Hwa-Jeong C. Flavonoid comprising anti-virus activity KR101334348. (2013).
Kim JW, Han JJ, Park EY, et al. Genistein derivatives and anti-fungal composition
containing the same WO2007061254. (2007).
Yuan J. Application of kaempferol as synergist of anti-fungal
medicaments CN102218052. (2012).
Kim C. Pharmaceutical compositions for preventing or treating
lung cancer comprising apigenin, curcumin, and honokiol as active
ingredients KR101803000. (2017).
Yang C. Applications of apigenin for preparation of medicines
inhibiting liver cancer epithelial-mesenchymal transition CN106377522. (2017).
Kim BB. Method for improving anti-cancer effect of apigenin by
irradiation and pharmaceutical composition for treating or preventing
cancer comprising irradiated apigenin KR20160132185. (2016).
Song KH. Pharmaceutical composition for preventing or treating
choriocarcinoma comprising apigenin, chrysophanol or mixture
thereof KR20180132212. (2018).
Jiang BH. Apigenin for chemoprevention, and chemotherapy
combined with therapeutic reagents US8377918. (2013).
Liu Y. Safe natural pharmaceutical composition for treating cancer US20040072790. (2004).
Cohen I. Methods and compositions for the treatment of cancer AU2009289644. (2010).
Lei Z. Pharmaceutical composition having apigenin and apigenin
derivative as well as histone deacetylase inhibitors and application
thereof CN102441167. (2014).
He B, You L, Xu Z, Jablons DM. Methods for treating cancer
by inhibiting Wnt signaling US20090304695. (2009).